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EFFECTIVENESS OF I AND II LINE CHEMO-TARGETED THERAPY 
ACCORDING TO THE SCHEME OXALIPLATIN + CAPECITABINE + 
BEVACIZUMAB (XELOX + BEV) IN PATIENTS WITH METASTATIC 
COLORECTAL CANCER (MCRC) 
The research involved 38 mCRC patients, aged 23-73 (medium 
age  -55  years). Patients  with  mCRC  were  randomized  into  two 
groups. This mode of chemo-targeted therapy was conducted in 
the first group (20 patents) in a second line, since these patients 
previously were treated by the chemotherapy schemes FOLFIRI 
or FOLFOX.  Patients were treated in the mode: Capecitabine in 
2000mg/m2 2 times a day from the 1st to the 14th day, 2-hour 
infusion of capsular Oxaliplatin 130mg/m2, day 1, Bevacizumab 
5mg/kg 1 time per 14 days. 
The overall objective effect was obtained in 15 patients (39.5±7.9) 
%: in group 1 - in 7 patients (35.0 + 10.6%), in the 2group - 8 
cases (44.4±11.7%), of which complete regression - in 1 (5%) and 
2 (11.1%) cases, respectively. In 30% of cases the partial response 
and  a  greater  number  of  stabilization  (50%  and  44.5% 
respectively)  were  reported.  Progression  of  the  process  was 
observed at 15% in a group 1 and 11.1% of cases in group 2. 
Terms of remission were group 1 - 8.2 months, group 2 - 12.1 
months. 
Thus, XELOX + BEV shows the sufficient efficacy in patients 
with  mCRC,  both  in  I  and  II  lines  of  chemotherapy,  with  an 
acceptable toxicity profile. 
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Relevance and purpose of research 
Due to high frequency of propagation and low survival of patients, a colorectal cancer 
became a relevant issue in present oncology, 1 234 000 cases of colorectal cancers are 
registered per year in the world (GLOBOCAN 2008). In 2009 there were registered 1224 
new  cases  of  colon  cancer  and  1140  cases  of  rectum  cancer  in  the  Republic  of 
Kazakhstan.  If  one  will  sum  up  these  figures  and  combine  two  localizations  under 
colorectal cancer, that disease will be in 4th place in the structure of oncologic morbidity 
(Arzykulov et al., 2010). 
Chemotherapy  of  colon  cancer  was  improved  due  to  integration  of  the  following 
medicines in the complex treatment: oxaliplatin, irinotecan, new peroral Capecitabine - 
xeloda, and target medicines - bevacizumab and cetuximab. 
In  metastatic  colon  cancer  the  most  effective  medicine  of  platinum  based  ones  is 
oxaliplatin.    Adding  oxaliplatin  to  5-fluorouracil  with  leucovorin  let  us  increase  the 
effectiveness  of  treatment  by  28.4%  and  survival  by  2.8  months  in  comparison  with 
treatment in Mayo mode. In order to increase the effectiveness of a first-line treatment of 
colorectal cancer some research of the combined use of oxaliplatin and irinotecan + 5-
fluorouracil / leucovorin was made. The overall response rate ranged from 42 to 78% 
according to various authors (Goldberg et al., 2004; Schalhorn et al., 2005). However, the 
addition of irinotecan to oxaliplatin in the 1st line treatment of colorectal cancer is not 
justified,  because  this  combination  significantly  limits  the  ability  of  the  2nd  line,  not Medical and Health Science Journal / MHSJ  /  ISSN: 1804-1884 (Print) 1805-5014 (Online)   
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increasing the effectiveness of treatment. Capecitabine (Xeloda), which has equal efficacy 
and  less  toxicity  with  5-fluorouracil/leucovorin  (Van  Cutsem  et  al.  2001;  Hoff  et  al., 
2001), allows you to include the drug in the modern chemotherapy regimens for mCRC. 
Bevacizumab -the recombinant monoclonal antibodies which block the different isoforms 
of VEGF (Arzykulov et al., 2010; Goldberg et al., 2004; Schalhorn et al., 2005). Vascular 
endothelial growth factor (VEGF) is a powerful angiogenic factor. It serves as a factor in 
prolonging the life of endothelial cells through inhibition of apoptosis. Hyperexpression 
of  VEGF  is  seen  in  70-80%  of  patients. By  2009  it became  known  that  addition  of 
bevacizumab  to  multiple  active  drug  therapy  regimens  increased  the  median  of 
progression-free and overall survival of mCRC patients. The effectiveness of bevacizumab 
in combination with chemotherapy can be assessed in the following studies: Saltz et al., 
2000, Kabbinavar et al., 2005, and Hurwitz et al., 2004, where the median of overall 
survival in the group of patients treated by bevacizumab ranges from 16.6 to 20.3 months 
(Saltz et al., 2000; Kabbinavar et al., 2005; Hurwitz et al., 2004). In combination with 
oxaliplatin-containing regimes bevacizumab is at the forefront in the treatment of mCRC, 
significantly improving the effectiveness of treatment and overall survival compared with 
the  single  chemotherapy.  All  of  the  above  mentioned  can  be  considered  relevant  for 
clinical studies aimed at optimizing the systemic therapies of mCRC. 
The  study  discusses  increasing  efficiency  in  the  treatment  of  patients  with  metastatic 
colorectal cancer. 
Materials and methods 
The study included 38 patients with mCRC, aged 23-73 (mean age -55 years): there were 
16 men (42.1%) and 22 female (57.9%). General condition of patients on the Karnofsky 
scale - not less than 70%. Stages of the disease: T3N0-2M1-10 (26.3%), T4N1-2M1-8 
(15.8%), T2-3N0-2M0-10(31.6%), T4N1-2M0-10 (26.3%). 
Previously,  the  combined  treatment  of  20  patients  was  performed  (surgery  + 
chemotherapy). All of these patients came for treatment with disease progression after I-
line chemotherapy under FOLFIRI or FOLFOX schemes (group 1). The remained 18 
patients with mCRC entered the hospital for the first time (group 2). Lesion volume did 
not exceed 60% in case liver metastases (23-60.5%), while preserving its functionality. And 
3 patients had the liver metastases combined with bone metastases of the skeleton, and 3 - 
with lung’s metastases. In 2 cases there was a combined metastatic lesion of bone and 
lung. In one case the lung’s metastases lesion was associated with ovarian cancer. As 
follow as from the above, the contingent of patients enrolled in the study had been very 
heavy. The diagnosis of all patients was verified histological. 
Mandatory morphological verification of liver metastases was not assumed. 
Patients were treated in the mode: Capecitabine in 2000mg/m2 2 times a day from the 1st 
to the 14th day, 2 - hour infusion of capsular oxaliplatin 130mg/m2, day 1, Bevacizumab 
5mg/kg 1 time per 14 days. Antiemetics were ordered for cause. The use of colony-
stimulating factors was not regulated. 
The  objective  effect  was  evaluated  after  3-4  courses  of  chemotherapy,  according  to 
Response Evaluation Criteria in Solid Tumors Group (RECIST). Assessment of the lesion 
was  performed  by  ultrasound  investigation  (U.S.),  X-ray  computed  (CT)  or  magnetic 
resonance imaging (MRI). 
Results 
The overall objective effect was obtained in 15 patients (39.5±7.9) %: in group 1 - 7 cases 
(35.0+10.6%), in 2 group - 8cases (44.4+11.7%), including a complete involution - in 1 
(5%) and 2 (11.1%) cases, respectively. In 30% of cases the partial response and a greater 
number of stabilization were reported (50% and 44.5% respectively). Medical and Health Science Journal / MHSJ  /  ISSN: 1804-1884 (Print) 1805-5014 (Online)   
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Progression of the process of 15% observed in group 1 and 11.1% of cases in group 2 
(Table 1). 
TABLE 1. THE EFFECTIVENESS OF TREATMENT 
  Full effect  Partial effect  Stabilization  Progression 
1group (n-20)  1 (5%)  6 (30%)  10 (50%)  3 (15%) 
2 group (n-18)  2 (11,1%)  6 (33,3%)  8 (44,5%)  2 (11,1%) 
Note: Period of remission: 1-st group - 8.2 month, 2-nd group - 12.1 month. 
 
The satisfactory subjective tolerability of combination XELOX + bevacizumab should be 
noted.  Nausea  and  vomiting  were  stopped  easily.  No  cases  of  febrile  neutropenia 
documented; however, 6 cycles of chemotherapy were delayed for a period of 1 to 2 
weeks for normalization of peripheral blood. Diarrhea was usually of I and II levels, it was 
relieved  by  standard  loperamide  therapy.  Neuropathy  appeared  in  case  of  III  and  IV 
toxicity levels it affected the quality of patient’s life. Prescribing of group B vitamins 
allowed reducing some symptoms of peripheral neuropathy. Hand-foot syndrome (HFS) 
developed mostly after the third course of chemotherapy, but the severity was not greater 
than II degree. Hypertension and epistaxis, typical side effects which occur when using 
bevacizumab, were of I and II toxicity levels. Hypertension was stopped through taking of 
the  standard  antihypertensive  therapy;  epistaxis  required  only  topical  treatment  it  was 
eliminated within 3 days on average. 
Thus,  XELOX  +  Bev  demonstrate  the  sufficient  efficacy  in  patients  with  metastatic 
colorectal cancer, both in I and II lines of chemotherapy, with an acceptable toxicity 
profile. 
Bevacizumab in combination with oxaliplatin and capecitabine applied to the patients with 
metastatic colorectal cancer has been accompanied by low risk of complications, improves 
the treatment outcomes and increases a period preceding a progression, which gives a 
hope for improving of the long-term results of treatment of such patients. 
In conclusion, XELOX + Bev show the sufficient efficacy in patients with mCRC, both 
in I and II lines of chemotherapy, with an acceptable toxicity profile. 
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